Current Awareness
2000; Wiley; Volume: 15; Issue: 4 Linguagem: Inglês
10.1002/1099-1077(200006)15
ISSN1099-1077
Tópico(s)Attention Deficit Hyperactivity Disorder
ResumoHuman Psychopharmacology: Clinical and ExperimentalVolume 15, Issue 4 p. 309-314 Current Awareness Current Awareness First published: 04 July 2000 https://doi.org/10.1002/1099-1077(200006)15:4 3.0.CO;2-9AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of human psychopharmacology. Each bibliography is divided into 18 sections: 1 Books, Reviews & Symposia; 2 General; 3 Psychotropic Drugs - General; Antidepressive Agents: 4 Tricyclics; 5 Monoamine Oxidase Inhibitors; 6 Serotonergics; Euthymic Agents: 7 Lithium; Tranquillizing Agents: 8 Major; 9 Minor & Hypnotics; 10 Analeptic Agents; 11 Anticonvulsant Agents; 12 Drugs of Abuse; 13 Transmitters, Receptors, Metabolites & Modulating Agents; 14 Neuropeptides; 15 Psychoneuroendocrinology; 16 Psychoneuroimmunology; 17 Behavioural Genetics; 18 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. Current Awareness 1. Books, reviews & symposia Google Scholar (1999). Special issue: Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. Eur Arch Psychiat Clin Neurosci 249 Google Scholar (1999). Special issue: Benzodiazepine dependence and withdrawal - Myths and management. J Clin Psychopharmacol 19 Google Scholar (1999). Special issue: Fifty Years of treatments for Bipolar Disorder - A celebration of John Cade's discovery. Aust N Z J Psychiatry 33 Google Scholar (1999). Special issue: Learning from our patients - Key issues in the clinical treatment of schizophrenia from a longitudinal perspective (Contains many papers on quetiapine). J Clin Psychiatry 60 Google Scholar (1999). Special issue: Pharmacologic treatments in schizophrenia and their effect on cognitive function. Psychiatr Ann 29 Google Scholar (1999). Special issue: Pharmacotherapy algorithms. Psychiatr Clin Neurosci 53 Google Scholar (1999). Special issue: Psychopharmacology in developmental disabilities. Ment Retard Dev Disabil Res 5 Google Scholar (1999). Special issue: Weight gain associated with the use of psychotropic medications. J Clin Psychiatry 60 Google Scholar (1999). Special section: Norepinephrine - New vistas for an old neurotransmitter. Biol Psychiatry 46 1124-1130 PubMedWeb of Science®Google Scholar Baldwin DS, Carabal E. (1999). Reboxetine, a selective noradrenaline reuptake inhibitor for the treatment of depression (Review). Drugs Today 35 719-724 PubMedWeb of Science®Google Scholar Baptista T, Lacruz A, De Mendoza S, Guillen MM, Burguera JL, De Burguera M, Hernandez L. (2000). Endocrine effects of lithium carbonate in healthy premenopausal women: Relationship with body weight regulation. Prog Neuropsychopharmacol Biol Psychiatry 24 1-16 PubMedWeb of Science®Google Scholar Brown ES, Khan DA, Nejtek VA. (1999). The psychiatric side effects of corticosteroids (Review). Ann Allergy Asthma Immunol 83 495-504 Google Scholar Buur-Rasmussen B, Brosen K. (1999). Cytochrome P450 and therapeutic drug monitoring with respect to clozapine (Review). Eur Neuropsychopharmacol 9 453-460 Google Scholar Davis JM, Janicak PG, Hogan DM. (1999). Mood stabilizers in the prevention of recurrent affective disorders: A meta-analysis (Review). Acta Psychiatr Scand 100 406-417 PubMedWeb of Science®Google Scholar De Lima MS, Hotoph M, Wessely S. (1999). The efficacy of drug treatments for dysthymia: A systemic review and meta-analysis. Psychol Med 29 1273-1290 Google Scholar Delgado PL, Michaels T. (1999). Reboxetine: A review of efficacy and tolerability (Review). Drugs Today 35 725-738 Google Scholar Goldman-Rakic PS. (1999). The relevance of the dopamine-D1 receptor in the cognitive symptoms of schizophrenia. Neuropsychopharmacology 21 S170-S180 Google Scholar Gurling HMD, Cook CCH. (1999). The genetic predisposition to alcohol dependence. Curr Opin Psychiatry 12 269-276 Google Scholar Hajak G. (1999). A comparative assessment of the risks and benefits of zopiclone: A review of 15 years' clinical experience. Drug Saf 21 457-470 Google Scholar Harrison PJ. (1999). The neuropathological effects of antipsychotic drugs (Review). Schizophr Res 40 87-99 PubMedWeb of Science®Google Scholar Heim C, Ehlert U, Hellhammer DH. (2000). The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology 25 1-35 PubMedWeb of Science®Google Scholar Heininger K. (1999). A unifying hypothesis of Alzheimer's disease. II. Pathophysiological processes. Hum Psychopharmacol Clin Exp 14 525-581 Google Scholar Miller A. (1999). Appropriateness of psychostimulant prescription to children: Theoretical and empirical perspectives (Review). Can J Psychiatry 44 1017-1024 PubMedWeb of Science®Google Scholar Nakazato A, Okuyama S. (2000). Recent advances in novel atypical antipsychotic agents: Potential therapeutic agents for the treatment of schizophrenia. Exp Opin Ther Patents 10 75-110 Google Scholar Nelson JC. (1999). A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression (Review). Biol Psychiatry 46 1301-1308 PubMedWeb of Science®Google Scholar Noble S, Benfield P. (1999). Amisulpride: A review of its clinical potential in dysthymia. CNS Drugs 12 471-484 Google Scholar Parker G, Mitchell P, Wilhelm K, Menkes D, Snowdon J, Schweitzer I, Grounds D, Skerritt P, Roy K, Hadzi-Pavlovic D. (1999). Are the newer antidepressant drugs as effective as established treatments? Results from an Australasian clinical panel review. Aust N Z J Psychiatry 33 874-881 PubMedWeb of Science®Google Scholar Remington G, Chong SA. (1999). Conventional versus novel antipsychotics: Changing concepts and clinical implications (Review). J Psychiatry Neurosci 24 431-441 PubMedWeb of Science®Google Scholar Sedvall GC, Karlsson P. (1999). Pharmacological manipulation of D1-dopamine receptor function in schizophrenia. Neuropsychopharmacology 21 S181-S188 Google Scholar Stiefel F, Berney A, Mazzocato C. (1999). Psychopharmacology in supportive care in cancer: A review for the clinician - I. Benzodiazepines. Support Care Cancer 7 379-385 PubMedWeb of Science®Google Scholar Tanaka E. (1999). Clinically significant pharmacokinetic drug interactions with benzodiazepines (Review). J Clin Pharm Ther 24 347-355 PubMedWeb of Science®Google Scholar Tandon R, Taylor SF, De Quardo JR, Eiser A, Jibson MD, Goldman M. (1999). The cholinergic system in schizophrenia reconsidered: Anticholinergic modulation of sleep and symptom profiles. Neuropsychopharmacology 21 S189-S202 Web of Science®Google Scholar Trollor JN, Sachdev PS. (1999). Electroconvulsive treatment of neuroleptic malignant syndrome: A review and report of cases. Aust N Z J Psychiatry 33 650-659 PubMedWeb of Science®Google Scholar Valmana A. (1999). Nonmethadone pharmacotherapies in opioid addiction. Curr Opin Psychiatry 12 307-310 Google Scholar 2. General Google Scholar Allain H, Bourin M, Reymann JM, Bentue-Ferrer D, Patat A, Schuck S, Lieury A. (1999). Emotion, anxiolysis and memory. Hum Psychopharmacol Clin Exp 14 S80-S86 Web of Science®Google Scholar Angst J. (1999). Modern epidemiology of anxiety: Results of The Zurich Cohort Study. Hum Psychopharmacol Clin Exp 14 S29-S37 Google Scholar Cannon M, Jones P, Huttunen MO, Tanskanen A, Murray RM. (1999). Motor co-ordination deficits as predictors of schizophrenia among Finnish school children. Hum Psychopharmacol Clin Exp 14 491-497 Google Scholar Cassano GB, Frank E, Maser JD, Shear MK, Rotondo A, Mauri M, Dell'Osso L. (1999). The panic-agoraphobic spectrum. Hum Psychopharmacol Clin Exp 14 S38-S44 Web of Science®Google Scholar Hantouche EG, Vahia VN. (1999). Interactions between psychotherapy and drug therapy in generalized anxiety disorder. Hum Psychopharmacol Clin Exp 14 S87-S93 Web of Science®Google Scholar Hindmarch I, Cockle SM, Stanley N. (1999). The anatomy of a clinical trial. Hum Psychopharmacol Clin Exp 14 S103-S108 Web of Science®Google Scholar Labelle A, Boulay LJ, Lapierre YD. (1999). Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia. Can J Psychiatry 44 887-892 PubMedWeb of Science®Google Scholar Lindley CR, Coyle JT. (1999). Psychopharmacologist as family doctor: Complications in the joint treatment of a husband and wife. Harv Rev Psychiatry 7 222-229 PubMedWeb of Science®Google Scholar Pichot P. (1999). The semantics of anxiety. Hum Psychopharmacol Clin Exp 14 S22-S28 Google Scholar Prochiantz A. (1999). Homeoproteins and the molecular basis of neuronal morphological plasticity. Hum Psychopharmacol Clin Exp 14 S11-S15 Google Scholar Reilly CE, Sokol L, Butler AC. (1999). A cognitive approach to understanding and treating anxiety. Hum Psychopharmacol Clin Exp 14 S16-S21 Google Scholar Roth M, Mountjoy C. (1999). Classification and diagnosis of the anxiety and depressive disorders and some implications for clinical practice and enquiry. Hum Psychopharmacol Clin Exp 14 S60-S71 Web of Science®Google Scholar Walker MP, Ayre GA, Ashton CH, Marsh VR, Wesnes K, Perry EK, O'Brien JT, McKeith IG, Ballard CG. (1999). A psychophysiological investigation of fluctuating consciousness in neurodegenerative dementias. Hum Psychopharmacol Clin Exp 14 483-489 Google Scholar 3. Psychotropic drugs - General Google Scholar Alison P et al. (1999). Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Eur J Clin Pharmacol 55 685-690 PubMedGoogle Scholar Bagby RM, Rector NA, Segal ZV, Joffe RT, Levitt AJ, Kennedy SH, Levitan RD. (1999). Rumination and distraction in major depression: Assessing response to pharmacological treatment. J Affect Disord 55 225-230 Google Scholar Barnard EJ, Venter KF. (1999). Antidepressant therapy in high-risk patients. S Afr Med J 89 995-999 Google Scholar Biederman J, Mick E, Prince J, Bostic JQ, Willens TE, Spencer T, Wozniak J, Faraone SV. (1999). Systematic chart review of the pharmacologic treatment of comorbid attention deficit hyperactivity disorder in youth with bipolar disorder. J Child Adolesc Pyschopharmacol 9 247-256 Google Scholar Blakley BW. (1999). Antidepressants and dizziness. J Otolaryngol 28 313-317 PubMedWeb of Science®Google Scholar Brown MCJ, Van Loon JMT, Guest JF. (1999). Cost-effectiveness of mirtazapine relative to amitriptyline in the treatment of moderate and severe depression in France. Eur J Psychiatry 13 197-208 Google Scholar Cadieux RJ. (1999). Antidepressant drug interactions in the elderly: Understanding the P-450 system is half the battle in reducing risks. Postgrad Med 106 231-240 Google Scholar Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JAG, Berecz R, Duran M, Benitez J. (1999). Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol 19 494-499 Google Scholar Dannon PN, Iancu I, Grunhaus L. (1999). Naltrexone treatment in kleptomanic patients. Hum Psychopharmacol Clin Exp 14 583-585 Google Scholar Ferrando SJ, Rabkin JG, De Moore GM, Rabkin R. (1999). Antidepressant treatment of depression in HIV-seropositive women. J Clin Psychiatry 60 741-746 PubMedWeb of Science®Google Scholar Franklin ME, Foa EB, Kozak MJ. (1999). Time-limited cognitive-behavioral therapy and pharmacotherapy of obsessive-compulsive disorder. Crisis Interv Time-Ltd Treat 5 37-57 Google Scholar Galanter CA, Wasserman G, Sloan RP, Pine DS. (1999). Changes in autonomic regulation with age: Implications for psychopharmacologic treatments in children and adolescents. J Child Adolesc Psychopharmacol 9 257-266 Google Scholar George T, Theodoros MT, Chiu E, Krapivensky N, Hokin A, Tiller JWG. (1999). An open study of sertraline in patients with major depression who failed to respond to moclobemide. Aust N Z J Psychiatry 33 889-895 PubMedWeb of Science®Google Scholar Gutierrez MA, Stimmel GL, Yi DD. (1999). Reboxetine: A selective norepinephrine reuptake inhibitor for the treatment of major depression. Formulary 34 909-919 Google Scholar Hassler F, Fegert JM. (1999). Psychopharmacological treatment for self-injurious behaviour of mentally retarded (German). Nervenarzt 70 1025-1028 PubMedWeb of Science®Google Scholar Hendrick V, Gitlin M, Altshuler L, Korenman S. (2000). Antidepressant medications, mood and male fertility. Psychoneuroendocrinology 25 37-52 Google Scholar Hickie IB, Scott EM, Davenport TA. (1999). Are antidepressants all the same? Surveying the opinions of Australian psychiatrists. Aust N Z J Psychiatry 33 642-649 PubMedWeb of Science®Google Scholar Hoehn-Saric R, Ninan P, Black DW, Stahl S, Greist JH, Lydiard B, McElroy S, Zajecka J, Chapman D, Clary C, Harrison W. (2000). Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive compulsive and major depressive disorders. Arch Gen Psychiatry 57 76-82 PubMedWeb of Science®Google Scholar Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J, Wong C, Simeon D. (1999). Clomipramine vs desipramine crossover trial in body dysmorphic disorder: Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry 56 1033-1040 Google Scholar Kane JM. (1999). Pharmacologic treatment of schizophrenia. Biol Psychiatry 46 1396-1408 PubMedWeb of Science®Google Scholar Katona C, Bercoff E, Chiu E, Tack P, Versiani M, Woelk H. (1999). Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: A double-blind randomised trial. J Affect Disord 55 203-214 Google Scholar Keks NA, Altson K, Hope J, Krapivensky N, Culhane C, Tanaghow A, Doherty P, Bootle A. (1999). Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 33 896-901 PubMedWeb of Science®Google Scholar Lader M. (1999). Anxiolytic effect of hydroxyzine: A double-blind trial versus placebo and buspirone. Hum Psychopharmacol Clin Exp 14 S94-S102 Web of Science®Google Scholar Leonard BE. (1999). New developments in the pharmacological treatment of anxiety. Hum Psychopharmacol Clin Exp 14 S52-S59 Web of Science®Google Scholar Mackay FR, Dunn NR, Martin RM, Pearce GL, Freemantle SN, Mann RD. (1999). Newer antidepressants: A comparison of tolerability in general practice. Br J Gen Pract 49 892-896 PubMedWeb of Science®Google Scholar Mamdani M, Herrmann N, Austin P. (1999). Prevalence of antidepressant use among older people: Population-based observations. J Am Geriatr Soc 47 1350-1353 PubMedWeb of Science®Google Scholar Moreau X, Azorin JM, Lejeune PJ, Jeanningros R. (2000). Red blood cell triiodothyronine uptake in unipolar major depression: Effect of a chronic antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry 24 23-38 Google Scholar Mynors-Wallis LM, Gath DH, Day A, Baker F. (2000). Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. Br Med J 320 26-30 Google Scholar Philipp M, Kohnen R, Hiller KO. (1999). Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. Br Med J 319 1534-1538 Web of Science®Google Scholar Phillips CD, Spry KM, Sloane PD, Hawes C. (2000). Use of physical restraints and psychotropic medications in Alzheimer special care units in nursing homes. Am J Public Health 90 92-96 PubMedWeb of Science®Google Scholar Riedel-Heller SG, Stelzner G, Schork A, Angermeyer MC. (1999). Psychotropic drug use in residential and nursing homes (German, English Abstract). Psychiatr Prax 26 273-276 PubMedWeb of Science®Google Scholar Rojas-Fernandez C, Thomas VS, Carver D, Tonks R. (1999). Suboptimal use of antidepressants in the elderly: A population-based study in Nova Scotia. Clin Ther 21 1937-1950 PubMedWeb of Science®Google Scholar Smith DF. (1999). Neuroimaging of serotonin uptake and antidepressant binding sites in the thalamus of humans and ‘higher’ animals. Eur Neuropsychopharmacol 9 537-544 PubMedWeb of Science®Google Scholar Stevinson C, Ernst E. (1999). Hypericum for depression: An update of the clinical evidence. Eur Neuropsychopharmacol 9 501-506 Google Scholar Uhlenhuth EH, Balter MB, Ban TA, Yang K. (1999). Trends in recommendations for the pharmacotherapy of anxiety disorders by an international expert panel, 1992-1997. Eur Neuropsychopharmacol 9 393-398 Google Scholar Versiani M, Ontiveros A, Mazzotti G, Ospina J, Davila J, Mata S, Pacheco A, Plewes J, Tamura R, Palacios M. (1999). Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): A double-blind comparison. Int Clin Psychopharmacol 14 321-328 Google Scholar Wilson KCM, Copeland JRM, Taylor S, Donoghue J, McCracken CFM. (1999). Natural history of pharmacotherapy of older depressed community residents: The MRC-ALPHA Study. Br J Psychiatry 175 439-443 PubMedWeb of Science®Google Scholar Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. (2000). Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 157 124-126 PubMedWeb of Science®Google Scholar Ziguras S, Lambert TJR, McKenzie DP, Pennella J. (1999). The influence of client's ethnicity on psychotropic medication management in community mental health services. Aust N Z J Psychiatry 33 882-888 PubMedWeb of Science®Google Scholar 4. Antidepressive agents: 4. Tricyclics Google Scholar Marraccini RL, Reynolds CF, Houck PR, Miller MD, Frank E, Perel JM, Cornes C, Mazumdar S, Kupfer DJ. (1999). A double-blind, placebo-controlled assessment of nortriptyline's side-effects during 3-year maintenance treatment in elderly patients with recurrent major depression. Int J Geriatr Psychiatry 14 1014-1018 PubMedWeb of Science®Google Scholar 5. Monoamine oxidase inhibitors Google Scholar Jungerman T, Rabinowitz D, Klein E. (1999). Deprenyl augmentation for treating negative symptoms of schizophrenia: A double-blind, controlled study. J Clin Psychopharmacol 19 522-525 PubMedWeb of Science®Google Scholar 6. Serotonergics Google Scholar Brody AL, Saxena S, Silverman DHS, Alborzian S, Fairbanks LA, Phelps ME, Huang SC, Wu HM, Maidment K, Baxter LR. (1999). Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res Neuroimaging 91 127-140 Google Scholar De Vane CL, Ware MR, Emmanuel NP, Brawman-Mintzer O, Morton WA, Villarreal G, Lydiard RB. (1999). Evaluation of the efficacy, safety and physiological effects of fluvoxamine in social phobia. Int Clin Psychopharmacol 14 345-352 Google Scholar Greenblatt DJ, Von Moltke LL, Hermatz JS, Shader RI. (1999). Human cytochromes mediating sertraline biotransformation: Seeking attribution. J Clin Psychopharmacol 19 489-493 PubMedWeb of Science®Google Scholar Kapitan T, Schindl M, Schindler SD, Hesselmann B, Fureder T, Barnas C, Sieghart W, Kasper S. (1999). The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res 88 75-88 PubMedWeb of Science®Google Scholar Kelly JP, Nicolau G, Redmond A, Leonard BE, Noble J, Sverdlov L, Molinar R, Kastin AJ, Ehrensing RH, Feighner JP. (1999). The effect of treatment with a new antidepressant, INN 00835, on platelet serotonin uptake in depressed patients. J Affect Disord 55 231-236 Google Scholar Leinonen E, Skarstein J, Behnke K, Agren H, Helsdingen JT. (1999). Efficacy and tolerability of mirtazapine versus citalopram: A double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol 14 329-338 Google Scholar Mackay FJ, Dunn NR, Mann RD. (1999). Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract 49 871-874 PubMedWeb of Science®Google Scholar Marazziti D, Rossi A, Dell'Osso L, Palego L, Placidi GPA, Giannaccini G, Lucacchini A, Cassano GB. (1999). Decreased platelet 3H-paroxetine binding in untreated panic disorder patients. Life Sci 65 2735-2742 Web of Science®Google Scholar New AS, Woo-Ming A, Mitropoulou V, Silverman J, Reynolds D, Schopick F, Trestman RL, Siever LJ. (1999). Serotonin and the prediction of response time to fluoxetine in patients with mild depression. Psychiatry Res 88 89-94 Google Scholar Poyurovsky M, Weizman A. (1999). Lack of efficacy of the 5-HT3 receptor antagonist granisetron in the treatment of acute neuroleptic-induced akathisia. Int Clin Psychopharmacol 14 357-360 PubMedWeb of Science®Google Scholar Ravindran AV, Lapierre YD, Anisman H. (1999). Obsessive-compulsive spectrum disorders: Effective treatment with paroxetine. Can J Psychiatry 44 805-807 PubMedWeb of Science®Google Scholar Riedel WJ, Schoenmakers E, Vermeeren A, O'Hanlon JF. (1999). The influence of trazodone treatment on cognitive functions in outpatients with major depressive disorder. Hum Psychopharmacol Clin Exp 14 499-508 Google Scholar Saxena S, Brody AL, Maidment KM, Dunkin JI, Colgan M, Alborzian S, Phelps ME, Baxter LR. (1999). Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 21 683-693 PubMedWeb of Science®Google Scholar Seedat S, Stein DJ. (1999). Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: An open trial. Int Clin Psychopharmacol 14 353-356 PubMedWeb of Science®Google Scholar Sigurdh J, Spigset O, Allard P, Mjorndal T, Hagglof B. (1999). Binding of [3H]lysergic acid diethylamide to serotonin 5-HT2A receptors and [3H]paroxetine to serotonin uptake sites in platelets from healthy children, adolescents and adults. Neuropsychobiology 40 183-187 PubMedWeb of Science®Google Scholar Toren P, Laor N, Cohen DJ, Wolmer L, Weizman A. (1999). Ondansetron treatment in patients with Tourette's syndrome. Int Clin Psychopharmacol 14 373-376 PubMedWeb of Science®Google Scholar Euthymic agents: 7 Lithium Google Scholar Frye MA, Denicoff KD, Bryan AL, Smith-Jackson EE, Alo SO, Luckenbaugh D, Leverich GS, Post RM. (1999). Association between lower serum free T4 and greater mood instability and depression in lithium-maintained bipolar patients. Am J Psychiatry 156 1909-1914 PubMedWeb of Science®Google Scholar Moore GJ, Bebchuk JM, Parrish JK, Faulk MW, Arfken CL, Strahl-Bevacqua J, Manji HK. (1999). Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am J Psychiatry 156 1902-1908 PubMedWeb of Science®Google Scholar Silverstone PH, Rotzinger S, Pukhovsky A, Hanstock CC. (1999). Effects of lithium and amphetamine on inositol metabolism in the human brain as measured by 1H and 31P MRS. Biol Psychiatry 46 1634-1641 PubMedWeb of Science®Google Scholar Wong SSL, Lee S, Wat KHY. (1999). A preliminary communication of an insight scale in the assessment of lithium non-adherence among Chinese patients in Hong Kong. J Affect Disord 55 241-244 PubMedWeb of Science®Google Scholar Yazici O, Kora K, Ucok A, Tunali D, Turan N. (1999). Predictors of lithium prophylaxis in bipolar patients. J Affect Disord 55 133-142 PubMedWeb of Science®Google Scholar Tranquillizing agents: 8 Major Google Scholar Battaglia J, Wolff TK, Wagner-Johnson DS, Rush AJ, Carmody TJ, Basco MR. (1999). Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department. Int Clin Psychopharmacol 14 361-372 PubMedWeb of Science®Google Scholar Berk M, Ichim L, Brook S. (1999). Olanzapine compared to lithium in mania: A double-blind randomized controlled trial. Int Clin Psychopharmacol 14 339-344 Google Scholar Burke JG, Dursun SM, Reveley MA. (1999). Refractory symptomatic schizophrenia resulting from frontal lobe lesion: Response to clozapine. J Psychiatry Neurosci 24 456-461 PubMedWeb of Science®Google Scholar Chou JCY, Czobor P, Charles O, Tuma I, Winsberg B, Allen MH, Trujillo M, Volavka J. (1999). Acute mania: Haloperidol dose and augmentation with lithium or lorazepam. J Clin Psychopharmacol 19 500-505 PubMedWeb of Science®Google Scholar Dittert S, Soyka M, Winter C, Moller HJ. (1999). Cognition and driving ability of schizophrenic patients on risperidone versus haloperidol (German). Fortschr Neurol Psychiatry S70-S73 Google Scholar Dorfman-Etrog P, Hermesh H, Prilipko L, Weizman A, Munitz H. (1999). The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: An open label study. Eur Neuropsychopharmacol 9 475-478 Google Scholar Drew LRH, Hodgson DM, Griffiths KM. (1999). Clozapine in community practice: A 3-year follow-up study ln the Australian Capital Territory. Aust N Z J Psychiatry 33 667-675 PubMedWeb of Science®Google Scholar Dursun SM, Szemis A, Andrews H, Reveley MA. (1999). The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: A prospective study. J Psychiatry Neurosci 24 453-455 PubMedWeb of Science®Google Scholar Emsley RA. (1999). Risperidone in the treatment of first-episode psychotic patients: A double-blind multicenter study. Schizophr Bull 25 721-730 Google Scholar Fischer B. (1999). Atypical neuroleptics in the treatment of schizophrenia (German). Nervenheilkunde 18 338-341 Google Scholar Fitzgerald P. (1999). Long-acting antipsychotic medication, restraint and treatment in the management of acute psychosis. Aust N Z J Psychiatry 33 660-666 PubMedWeb of Science®Google Scholar Fitzgerald PB, Kapur S, Caligiuri MP, Jones C, Silvestri S, Remington G, Zipursky RB. (2000). Instrumentally detected changes in motor functioning in patients with low levels of antipsychotic dopamine D2 blockade. Neuropsychopharmacology 22 19-26 PubMedWeb of Science®Google Scholar Gervin M, Browne S, Garavan J, Roe M, Larkin C, O'Callaghan E. (1999). Dysphoric subjective response to neuroleptics in schizophrenia: Relationship to extrapyramidal side effects and symptomatology. Eur Psychiatry 14 405-409 PubMedWeb of Science®Google Scholar Grabe HJ, Wolf T, Gratz S, Laux G. (1999). The influence of clozapine and typical neuroleptics on information processing of the central nervous system under clinical conditions in schizophrenic disorders: Implications for fitness to drive. Neuropsychobiology 40 196-201 PubMedWeb of Science®Google Scholar Grassi B, Ferrari R, Epifani M, Dragoni C, Cohen S, Scarone S. (1999). Clozapine lacks previous clinical efficacy when restarted after a period of discontinuation: A case series. Eur Neuropsychopharmacol 9 479-482 Google Scholar Hammond CM, Pierson JF, Grande TP, Munetz MR, Wilson DR, Pathak DS. (1999). Economic evaluation of risperidone in an outpatient population. Ann Pharmacother 33 1160-1166 PubMedWeb of Science®Google Scholar Kelly DL, Conley RR, Tamminga CA. (1999). Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res 40 101-104 PubMedWeb of Science®Google Scholar Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BPR, Van Royen EA. (1999). Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiatr Res Neuroimaging 92 33-44 Google Scholar Love RC, Conley RR, Kelly DL, Bartko JJ. (1999). A dose-outcome analysis of risperidone. J Clin Psychiatry 60 771-775 PubMedWeb of Science®Google Scholar Manschreck TC, Redmond DA, Candela SF, Maher BA. (1999). Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. J Neuropsychiatry Clin Neurosci 11 481-489 PubMedWeb of Science®Google Scholar Markianos M, Hatzimanolis J, Lykouras L. (1999). Switch from neuroleptics to clozapine does not influence pituitary-gonadal axis hormone levels in male schizophrenic patients. Eur Neuropsychopharmacol 9 533-536 PubMedWeb of Science®Google Scholar Melkersson KI, Hulting AL, Brismar KE. (1999). Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 60 783-798 Google Scholar Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. (1999). Active monitoring of 12760 clozapine recipients in the UK and Ireland: Beyond pharmacovigilance. Br J Psychiatry 175 576-580 PubMedWeb of Science®Google Scholar Osser DN, Nakarian DM, Dufresne RL. (1999). Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 60 767-770 PubMedWeb of Science®Google Scholar Peuskens J, Bech P, Moller HJ, Bale R, Fleurot O, Rein W. (1999). Amisulpride vs risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 88 107-118 Google Scholar Rosenheck R, Evans D, Herz L, Cramer J, Xu WC, Thomas J, Henderson W, Charney D. (1999). How long to wait for a response to clozapi
Referência(s)